Clinical Study Evaluating the Safety and Performance of the MIST Device for Intraocular Pressure Reduction in Patients With Primary Open-Angle Glaucoma

Inclusion Criteria: * Adults ≥ 40 years with uncontrolled mild to moderate POAG. * IOP ≥ 18 mmHg on ≥1 topical IOP-lowering medications. * Open angle on gonioscopy * Clear cornea and healthy ocular surface * Capable of giving informed consent, willingness to participate in the trial, and adhering to follow-up * Glaucomatous visual field loss in one or both eyes at presentation on any of these criteria: * Reproducible and reliable visual field defects on 2 consecutive fields * Mild, moderate or advanced disease on mean deviation according to Hodapp classification * Healthy, mobile conjunctiva in the target quadrant (superior bulbar region) * Best-corrected Snellen visual acuity of 20/100 or better * Visual field mean deviation no worse than -18.0 dB (without dense paracentral scotomas) * No anticipated need for other ocular surgeries (e.g., cataract) within 3 months of post-enrollment Exclusion Criteria: * Prior glaucoma filtering surgery (trabeculectomy, shunt or valve) in the treatment quadrant * Angle-closure, neovascular, uveitic, or traumatic glaucoma. * Eyes with conjunctival scarring, prior conjunctival surgery or other pathologies in the treatment quadrant * Eyes with scleral thinning, staphyloma, or structural abnormalities in the treatment quadrant * Uncontrolled IOP \> 35 mmHg at screening. * Active ocular infection or inflammation (e.g. blepharitis, conjunctivitis, keratitis, uveitis). * Active or recent (within 6 months) iris neovascularization in the treatment quadrant * Impaired episcleral venous drainage * Anterior chamber intraocular lens * Patients with uncontrolled bleeding disorders or those receiving anticoagulation therapy without appropriate perioperative management * Advanced glaucomatous optic neuropathy. * Fuchs endothelial dystrophy with clinical signs of endothelial decompensation. * Central corneal thickness (CCT) \> 600 μm. * Pathological myopia. * Patients unable to comply with postoperative follow-up or treatment instructions * Women who are (i) pregnant, (ii) nursing, (iii) planning a pregnancy and (iv) of childbearing potential not using a reliable method of contraception as outlined below are excluded: * Hormonal methods and the intrauterine device (IUD) must be in use at least 30 days prior to first study drug administration * Barrier methods must be in use at least 14 days prior to study drug administration * Your male partner vasectomy must be completed 3 months prior to first study drug administration or a sperm count of 0 should be confirmed.